Aratana Therapeutics Inc (NASDAQ:PETX) saw unusually-strong trading volume on Thursday . Approximately 251,111 shares changed hands during mid-day trading, a decline of 44% from the previous session’s volume of 446,934 shares.The stock last traded at $4.17 and had previously closed at $4.19.
A number of equities research analysts recently issued reports on PETX shares. Stifel Nicolaus reiterated a “hold” rating and issued a $6.00 price objective on shares of Aratana Therapeutics in a research report on Monday, December 18th. HC Wainwright set a $10.00 price objective on Aratana Therapeutics and gave the stock a “buy” rating in a research report on Thursday, December 21st. CL King initiated coverage on Aratana Therapeutics in a research report on Wednesday, December 27th. They set a “neutral” rating on the stock. ValuEngine downgraded Aratana Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Sunday, December 31st. Finally, Zacks Investment Research downgraded Aratana Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, January 17th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $8.39.
The company has a current ratio of 2.40, a quick ratio of 2.02 and a debt-to-equity ratio of 0.24. The stock has a market capitalization of $181.58, a PE ratio of -3.49 and a beta of 3.13.
Aratana Therapeutics (NASDAQ:PETX) last released its quarterly earnings results on Tuesday, March 13th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.23) by $0.04. Aratana Therapeutics had a negative return on equity of 45.15% and a negative net margin of 185.78%. The business had revenue of $10.46 million for the quarter, compared to the consensus estimate of $5.72 million. analysts expect that Aratana Therapeutics Inc will post -0.63 earnings per share for the current year.
In other Aratana Therapeutics news, CEO Peter Steven St sold 19,367 shares of the firm’s stock in a transaction dated Tuesday, January 30th. The stock was sold at an average price of $4.77, for a total transaction of $92,380.59. Following the sale, the chief executive officer now owns 672,259 shares in the company, valued at $3,206,675.43. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Craig A. Tooman sold 30,000 shares of the firm’s stock in a transaction dated Thursday, January 11th. The shares were sold at an average price of $5.27, for a total value of $158,100.00. Following the transaction, the insider now directly owns 75,024 shares in the company, valued at $395,376.48. The disclosure for this sale can be found here. Company insiders own 5.20% of the company’s stock.
Several large investors have recently made changes to their positions in the company. Parametric Portfolio Associates LLC grew its stake in shares of Aratana Therapeutics by 6.6% during the second quarter. Parametric Portfolio Associates LLC now owns 30,127 shares of the biopharmaceutical company’s stock valued at $218,000 after buying an additional 1,875 shares during the last quarter. Voya Investment Management LLC grew its stake in shares of Aratana Therapeutics by 22.7% during the second quarter. Voya Investment Management LLC now owns 19,530 shares of the biopharmaceutical company’s stock valued at $141,000 after buying an additional 3,610 shares during the last quarter. California State Teachers Retirement System grew its stake in shares of Aratana Therapeutics by 6.9% during the second quarter. California State Teachers Retirement System now owns 71,741 shares of the biopharmaceutical company’s stock valued at $519,000 after buying an additional 4,600 shares during the last quarter. The Manufacturers Life Insurance Company grew its stake in shares of Aratana Therapeutics by 25.3% during the second quarter. The Manufacturers Life Insurance Company now owns 34,176 shares of the biopharmaceutical company’s stock valued at $248,000 after buying an additional 6,898 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in shares of Aratana Therapeutics by 2.0% during the third quarter. Dimensional Fund Advisors LP now owns 388,437 shares of the biopharmaceutical company’s stock valued at $2,381,000 after buying an additional 7,542 shares during the last quarter. 71.07% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: This news story was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another site, it was illegally copied and republished in violation of United States and international copyright legislation. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/03/22/aratana-therapeutics-petx-sees-unusually-high-trading-volume.html.
About Aratana Therapeutics
Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.
Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.